A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs AZD 5363 (Primary) ; Fulvestrant
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FAKTION
- 13 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.
- 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Aug 2017 Planned End Date changed from 1 Aug 2016 to 1 Oct 2019.